The state of Texas currently has 224 active clinical trials seeking participants for Lung Cancer research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
A Study of GV20-0251 in Patients With Solid Tumor Malignancies
NCT05669430
Recruiting
This is a Phase 1 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: Oncology Consultants, P.A., Houston, Texas
Conditions: Solid Tumor, Adult, Refractory Cancer, Bladder Urothelial Carcinoma, Cholangiocarcinoma, Adenocarcinoma of the Colon, Endometrial Carcinoma, Head and Neck Carcinoma, Cutaneous Melanoma, Non-small Cell Lung Cancer, Adenocarcinoma of the Rectum
Register for Updates
Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors
NCT06040541
Recruiting
This study is to evaluate the safety and tolerability of RMC-9805 in adults with KRAS G12D-mutant solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/31/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas +2 locations
Conditions: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Register for Updates
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
NCT03504488
Recruiting
The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas +1 locations
Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
Register for Updates
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
NCT03881488
Recruiting
This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving an approved PD-1 or PD-L1 inhibitor. The study will be conducted in 2 treatment arms (Monotherapy Arm 1 and Combination Arm 2). Each arm will have two parts: Part 1 Dose Escalation and Part 2 Dose Expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer
Register for Updates
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
NCT04681131
Recruiting
The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas +1 locations
Conditions: Non-Small-Cell Lung Cancer
Register for Updates
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
NCT05704634
Recruiting
To learn if the combination of sarilumab (also called Kevzara) and cemiplimab can help to control EGFR- or LKB1/STK11-mutant NSCLC.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Register for Updates
A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors
NCT04892017
Recruiting
This is a Phase 1/2, multicenter, open label, first in human (FIH) study of DCC-3116 as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation phase, and an expansion phase.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/25/2024
Locations: NEXT Oncology, Austin, Texas +2 locations
Conditions: Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Melanoma, Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
A Phase 1 Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3 (the SKYBRIDGE Study)
NCT05652686
Recruiting
PT217 is a bispecific antibody (bsAb) against human DLL3 (huDLL3) and human CD47 (huCD47). This is an open label, Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of PT217 in subjects with advanced or refractory cancers. Patients with the following tumor types will be eligible for screening: unresectable small cell lung cancer (SCLC), large cell neuroendocrine cancer (LCNEC), neuroendocrine prostate cancer (NEPC) and gastroenteropancreatic neuro... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/25/2024
Locations: Mays Cancer Center / University of Texas, San Antonio, San Antonio, Texas
Conditions: Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
Register for Updates
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
NCT05563272
Recruiting
A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.
Gender:
All
Ages:
Between 18 years and 95 years
Trial Updated:
01/24/2024
Locations: Austin Radiological Association (ARA), Austin, Texas
Conditions: Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme, Cholangiocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Epithelial Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma
Register for Updates
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
NCT04982926
Recruiting
This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of TAS2940 in patients with advanced or metastatic solid tumors who are not candidates for approved or available therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/23/2024
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor, Glioblastoma, Non-small Cell Lung Cancer, Breast Cancer
Register for Updates
Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.
NCT06145048
Recruiting
This is a Phase 2, multi-center, open-label study to evaluate the safety and efficacy of VGT-309, a tumor-targeted, activatable fluorescent imaging agent, in subjects undergoing surgery for proven or suspected cancer in the lung. Approximately 100 subjects will be enrolled to ensure at least 86 subjects are evaluable with the option to expand enrollment by protocol amendment if deemed necessary by the DSC to meet primary and/or secondary objectives.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/23/2024
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer, Lung Metastases
Register for Updates
A Study to Investigate LYL845 in Adults With Solid Tumors
NCT05573035
Recruiting
This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
01/22/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
Register for Updates